Regular acetaminophen use and blood pressure in people with hypertension The PATH-BP Trial

SUPPLEMENTAL MATERIAL

PATH-BP list of authors and investigators

Authors

Iain M. MacIntyre[1,2] PhD

Emma J. Turtle[2] MD

Tariq E. Farrah[1,2] MBChB

Catriona Graham[3] MSc

James W. Dear[2] PhD

David J. Webb[2] DSc

Study Investigators

Morag McCallum[2] RN

Vanessa Melville[2] RN

Henry Fok[2] PhD

Jame C. McCrae[2] PhD

Ashish Sule[2] MD

Thomas M. Caparrotta[2] MBBCh

Sample analysis

Nicholas S. Kirkby[4] PhD

Jane A. Mitchell[4] PhD

Statistical analysis

Catriona Graham[3] MSc

1. Department of Renal Medicine, Royal Infirmary of Edinburgh, NHS Lothian, 51 Little France Crescent, Edinburgh, EH16 4SA, United Kingdom
2. University/British Heart Foundation Centre of Research Excellence, Centre for Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh, 47 Little France Crescent, Edinburgh, EH16 4TJ, United Kingdom
3. Edinburgh Clinical Research Facility, University of Edinburgh, Western General Hospital, Crewe Road South, Edinburgh, EH4 2XU, United Kingdom

4. Cardiothoracic Pharmacology, National Heart and Lung Institute, Imperial College London, SW7 2AZ, United Kingdom.

Figure S1. Study design



PATH-BP cross-over study design. Participants attended for 4 visits during each arm of the study (2 long and 2 short). Long visits (~1hr) at days 0 and 14 consisted of semi-automated clinic BPs (x3), blood sampling and fitting of an ambulatory BP monitor. Short visits (~30 minutes) at days 4 and 7 consisted of semi-automated clinic BPs (x3) and blood sampling.

Table S1. Baseline data for those that completed both arms of the study

	Acetaminophen-first (n = 53)	Placebo-first (n = 50)
Age (yrs.) (± SD)	61.1 (7.9)	62.1 (8.1)
Male sex – no. (%)	38 (72)	41 (82)
Smoking Status – no. (%) • Current • Ex-smoker • Never smoked	 2 (7) 17 (32) 34 (64)	 1 (2) 20 (40) 29 (58)
On treatment for hypertension – no. (%)	38 (72)	31 (62)
Antihypertensive treatment – no. (%) **ACE Inhibitor** **Angiotensin receptor blocker** **Calcium channel blocker** **Diuretic** **Beta-blocker**	 19 (36) 18 (34) 9 (17) 12 (23) 4 (8)	 12 (20) 15 (30) 13 (26) 16 (32) 3 (6)
Number of Antihypertensives – no. (%) **No antihypertensives** **1 Drug** **2 Drugs** **3 Drugs**	 15 (28) 20 (38) 12 (23) 6 (11)	 19 (38) 10 (20) 14 (28) 7 (14)
Statin therapy – no. (%)	15 (28)	10 (20)

Figure S2. Placebo-corrected change in systolic daytime ambulatory blood pressure from baseline.



Placebo-corrected change in average daytime systolic ambulatory BP from baseline. There was no statistical difference in systolic BP change between those participants treated and not treated for hypertension, p = 0.13

Figure S3. Placebo-corrected change in clinic blood pressure from baseline



The change in clinic systolic BP from baseline to day 4 ,7, 14, taking the difference between active and placebo phase. Values given are mean ± standard error.